Betibeglogene autotemcel Alternatives Compared
| Betibeglogene autotemcel | Reblozyl (luspatercept) | Luspatercept |
|
|---|
| Betibeglogene autotemcel | Reblozyl (luspatercept) | Luspatercept |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Beta Thalassemia. Betibeglogene autotemcel may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Myelodysplastic Syndrome, Beta Thalassemia, Anemia. Reblozyl may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Myelodysplastic Syndrome, Beta Thalassemia, Anemia. Luspatercept may also be used for purposes not listed in this medication guide. |
Related suggestions Beta Thalassemia
|
|||||||
| More about Betibeglogene autotemcel | More about Reblozyl (luspatercept) | More about Luspatercept | ||||||||
| Ratings & Reviews | ||||||||||
|
Be the first to share your experience with this drug. |
Reblozyl has an average rating of 9.2 out of 10 from a total of 6 ratings on Drugs.com. 83% of reviewers reported a positive effect, while 0% reported a negative effect. |
Luspatercept has an average rating of 8.2 out of 10 from a total of 9 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||
|
View all Reblozyl side effects |
View all Luspatercept side effects |
|||||||||
| Drug Class | ||||||||||
| Generic Availability | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Reblozyl prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | ||||||||||
|
N/A |
|
N/A |
||||||||
| Brand Names | ||||||||||
| Zynteglo |
N/A |
Reblozyl | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||
|
N/A |
264 hours |
264 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 44 drugs are known to interact with Betibeglogene autotemcel:
|
A total of 2 drugs are known to interact with Reblozyl:
|
A total of 2 drugs are known to interact with Luspatercept:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
N/A |
November 08, 2019 |
November 08, 2019 |
||||||||
| WADA Class View classifications | ||||||||||
|
N/A |
||||||||||
| More Information | ||||||||||
| Patient Resources | ||||||||||
| Professional Resources | ||||||||||
| Related Treatment Guide | ||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.